What it is
Oxytocin is a small hormone made in the brain and released from the pituitary gland. Its best-known jobs are making the womb contract during labour and making milk flow during breastfeeding. It also acts inside the brain, which is why researchers have looked at it in social behaviour.
As a medicine, oxytocin is a hospital drug. It is given through a drip or as an injection to start or strengthen labour when there is a medical reason, and to help the womb clamp down after birth to limit bleeding. Pitocin is the best-known US brand; generic versions are also approved.
Oxytocin sprayed into the nose, as studied in autism and psychiatry research, is a different matter. It is not what the US approvals cover.
Oxytocin is a cyclic nonapeptide amide (Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2, disulfide Cys1–Cys6; C43H66N12O12S2, 1007.2 g/mol). It acts on the oxytocin receptor (OXTR), a G protein-coupled receptor. In myometrium, the label describes contraction via increased intracellular Ca2+ and Ca2+-dependent myosin light-chain kinase; receptor density rises sharply in pregnancy, peaking in early labour at term, which explains the highly individual dose response.
Oxytocin differs from vasopressin at only two positions, and at high doses shows pressor and antidiuretic activity; the antidiuretic effect underlies water intoxication during prolonged infusion. Pharmacokinetics (label): distribution throughout extracellular fluid, small amounts reaching the fetus, plasma half-life about 1 to 6 minutes (shorter in late pregnancy and lactation), and clearance mainly by kidney and liver. After IV administration the uterine response is almost immediate and subsides within an hour; after IM injection it begins in 3 to 5 minutes and lasts 2 to 3 hours.
Who made it and when
Oxytocin was the first peptide hormone whose structure was worked out and then built in a laboratory. In 1953 the American biochemist Vincent du Vigneaud and his team at Cornell’s medical college in New York identified its nine building blocks and made it synthetically. He received the 1955 Nobel Prize in Chemistry for that work.
Making it in the lab mattered clinically, because pituitary extracts can carry related hormones such as vasopressin. Pitocin’s label notes that the drug is made synthetically to avoid that contamination. The molecule itself has long been off patent. Drugs@FDA lists the current US applications for Pitocin and for Fresenius Kabi’s generic injection with 1980 approval dates.
Du Vigneaud and colleagues reported the structure and total synthesis of oxytocin in 1953, the first synthesis of a polypeptide hormone; the Nobel committee cited his “first synthesis of a polypeptide hormone” in the 1955 Chemistry prize. The work established that a synthetic peptide could reproduce the biological activity of a pituitary extract.
Current US approvals: Drugs@FDA lists Pitocin under NDA 018261 (holder PH Health; label contact Par Pharmaceutical), approved 1980-11-19 with the latest label supplement in May 2021, and Fresenius Kabi’s Oxytocin Injection USP under NDA 018248, approved 1980-07-09 with a label update in September 2022. Both are 10 USP units per mL injections. No compound patent applies. Oxytocin is a peptide of nine amino acids, so it is regulated as a drug, not as a biological product; it was not part of the March 2020 transition that moved hCG and insulin to biologics licences.
What the data say
For its approved uses, oxytocin is the standard drug for preventing heavy bleeding after birth, and it is the usual comparison drug in trials of alternatives. In a trial of almost 30,000 women across 10 countries, a heat-stable alternative called carbetocin was shown to be no worse than oxytocin on the main bleeding measure after vaginal birth, though this could not be shown for very heavy bleeding of a litre or more.
The label is blunt about risks: too much can overwork the womb, and long infusions can cause dangerous water retention.
For uses outside labour, the evidence is much weaker. Small studies raised hopes that nasal oxytocin might improve social functioning in autism. A 2021 trial in 290 children and teenagers over six months found no difference from placebo. Research in other conditions was not reviewed for this article.
Obstetric evidence: in CHAMPION (Widmer et al., NEJM 2018; n=29,645), oxytocin 10 IU IM was the comparator for heat-stable carbetocin 100 µg IM; the composite of blood loss of at least 500 mL or additional uterotonic use was 14.4% vs 14.5% (RR 1.01, 95% CI 0.95–1.06), meeting noninferiority; for blood loss of at least 1000 mL (1.45% vs 1.51%) noninferiority was not shown. The label cites historical data showing infusion rates up to 6 mU/min reproduce oxytocin levels seen in spontaneous labour.
Intranasal research: SOARS-B (NCT01944046; Sikich et al., NEJM 2021) randomised 290 participants aged 3–17 with autism spectrum disorder to intranasal oxytocin (target 48 IU/day) or placebo for 24 weeks. The least-squares mean change on the Aberrant Behavior Checklist modified Social Withdrawal subscale was −3.7 vs −3.5 (difference −0.2, 95% CI −1.5 to 1.0, P=0.61); secondary social and cognitive outcomes did not differ, and adverse events were similar. The paper notes that oxytocin had already been given in clinical practice to many children with autism before this trial. Intranasal oxytocin has also been studied in other psychiatric and metabolic conditions; those trials were not reviewed for this article.
Regulatory picture
Three separate facts. Approval: oxytocin injection is FDA approved, but only for medically needed induction or strengthening of labour, certain miscarriage situations and bleeding after birth. The label states plainly that it is not indicated for elective induction, meaning induction for convenience without a medical reason. Nasal, oral and other uses are not approved. Compounding: pharmacies may not make copies of the approved injections, but because oxytocin is an ingredient of approved drugs and has an official USP standard, pharmacies can legally compound other forms, such as nasal sprays, for an individual prescription. That does not make those uses approved. Enforcement: no FDA warning letters specific to oxytocin were found.
Approval: approved. Pitocin (NDA 018261) and generic oxytocin injections are indicated antepartum for medically indicated induction, stimulation of labour in selected uterine inertia and as adjunctive therapy in incomplete or inevitable abortion, and postpartum to produce uterine contractions and control bleeding. The label’s Important Notice states that because data are inadequate to evaluate benefits and risks, Pitocin is not indicated for elective induction. For induction or augmentation, the label states it should be given only by IV infusion under medical supervision in hospital, with continuous observation.
Compounding: recorded as restricted, meaning copies of the approved products are not permitted outside shortage. Under section 503A a bulk substance with a USP monograph, or one that is a component of an FDA-approved drug, may be used, so patient-specific preparations that are not essentially copies (for example intranasal or sublingual forms) can fall within 503A if its other conditions are met; they are unapproved as finished products and are not FDA-reviewed for safety or effectiveness. Oxytocin is not on FDA’s Category 2 list.
